Skoro-Sajer N, et al. - The efficacy as well as safety analysis of subcutaneous treprostinil in adult patients with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) was carried out after 12 months of treatment. Findings were suggestive of general safety as well as efficacy of subcutaneous treprostinil therapy for at least 12 months and indicated that this therapy may be used in CHD-related PAH class III and IV.